View More Recent Stories
-
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
-
Alnylam Pharma (ALNY) out of the money July puts and January 260 calls active as share price up 38%
-
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
-
BMO Capital Reiterates Outperform Rating on Alnylam (ALNY), Sees Significant Upside Following Data
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharma (ALNY) Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran
-
Alnylam Pharma (ALNY) to Resume Trading at 7:30 a.m.
-
BridgeBio Pharma (BBIO) Trades Lower After Alnylam Pharma (ALNY) Reports Positive Data
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Top pharma stocks to own in 2024 – Citi

